February 2021 Volume 7 Issue 3

February 2021

Volume 7, Issue 3

This issue explores common pitfalls for doctors considering careers outside of patient care, new treatments for porphyrias, and more.

Table of Contents

February 2021 Issue

You Make the Call

Reader Responses: How would you treat this patient with poor cytogenetics and low-grade B-cell...

Monday, February 1st, 2021
Here’s how readers responded to a You Make the Call question about treatment of low-grade B-cell lymphoma with high-risk cytogenetics. Disclaimer: ASH does not recommend or...

The Future of Chronic Graft-Versus-Host Disease

Monday, February 1st, 2021
An Update From the 3rd NIH Chronic GVHD Consensus Conference In this edition, Steven Pavletic, MD, and Kirk Schultz, MD, report on the progress and...

Editor’s Corner: A Period Piece

Monday, February 1st, 2021
It happens every week in my clinic. I ask a patient one simple question and the floodgates open. I hear confessions of days upon...

February 2021 Issue

WIB_icon

Avelumab Shows Clinical Activity in Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma

Monday, February 1st, 2021
Avelumab is clinically active in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (ENKTL), although researchers observed a lower-than-expected response rate, according to...
WIB_icon

Leukemia Antigen–Specific Donor-Derived T Cells Enhance Graft-Versus-Leukemia Effects in Post-Transplant AML/MDS

Monday, February 1st, 2021
For patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) whose disease relapses following a hematopoietic cell transplantation (HCT), unselected donor lymphocytes typically...
WIB_icon

Researchers Develop a Validated Pediatric Disease Risk Index for AML and ALL

Monday, February 1st, 2021
A pediatric disease risk index (DRI) reported in Blood was capable of stratifying children with acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL)...
The Society Pages

Remembering James Cook, Oncology Researchers Receive 2020 NIH Director’s New Innovator Awards, and more

Monday, February 1st, 2021
Remembering James Cook (1936 – 2020) James D. Cook, MD, an esteemed teacher and mentor, passed away in November 2020. His research focused on iron...
ASH Directions

New Clinical Practice Guidelines for von Willebrand Disease, Announcing the 2021 ASH Scholar Award...

Monday, February 1st, 2021
Just Published: Clinical Practice Guidelines on the Diagnosis and Management of von Willebrand Disease The American Society of Hematology (ASH) has developed clinical practice guidelines for...

What Is the Best Method for Cytoreduction in Patients With Acute Myeloid Leukemia and...

Monday, February 1st, 2021
In patients with acute myeloid leukemia (AML), hyperleukocytosis is associated with the oncologic emergency leukostasis as well as inferior outcomes, but there are few...
WIB_icon

CONTRALTO: Evaluating a Chemotherapy-Free Approach With Venetoclax in Relapsed/Refractory Follicular Lymphoma

Monday, February 1st, 2021
A chemotherapy-free approach comprising venetoclax and rituximab (VEN+R) showed modest efficacy in the treatment of patients with relapsed/refractory follicular lymphoma and was outperformed by...

BOSTON: Selinexor Improves Progression-Free Survival in Relapsed/Refractory Myeloma

Monday, February 1st, 2021
The combination of once-weekly selinexor with bortezomib and dexamethasone (SVd) demonstrated a 30% reduction in the risk of disease progression or death, compared with...

New Rule Requires U.S. Hospitals and Insurers to Publicly Disclose Cost Information

Monday, February 1st, 2021
Effective January 11, 2021, the Trump administration’s Transparency in Coverage rule will require U.S. hospitals to publicly post their prices for each service they...

Convalescent Plasma Shows No Benefit in Patients With Severe COVID-19

Monday, February 1st, 2021
After finding no benefit, the international REMAP-CAP trial testing convalescent plasma for the treatment of patients with COVID-19 has halted enrollment of patients with...
Sickle cell anemia

First Patients to Receive CRISPR for SCD, Beta Thalassemia Continue to Improve

Monday, February 1st, 2021
Updated results published in the New England Journal of Medicine and presented at the 2020 American Society of Hematology (ASH) Annual Meeting show that...

HHS Extends Public Health Emergency, Including Telehealth Flexibility, Until April 2021

Monday, February 1st, 2021
The U.S. Department of Health and Human Services (HHS) Secretary Alex Azar has extended the public health emergency declaration around the COVID-19 pandemic for...

February 2021 Issue

The Doctor Is Out

Monday, February 1st, 2021
For doctors considering a career outside of patient care, experts offer advice for avoiding common pitfalls in the second of a two-part series With the...

Pulling Back the Curtain: Satish Gopal, MD, MPH

Monday, February 1st, 2021
In this edition, Satish Gopal, MD, MPH, talks about how being a second-generation Indian American informed his career in global health. Where did you grow...

February 2021 Issue

You Make the Call

You Make the Call: How would you treat this patient with poor cytogenetics and...

Monday, February 1st, 2021
This month, Jorge Castillo, MD, discusses treatment of low-grade B-cell lymphoma with high-risk cytogenetics. And don't forget to check out next month's clinical dilemma - send...

A Primer on Porphyrias

Monday, February 1st, 2021
Finding New Treatments for These Rare, Often Misdiagnosed, Disorders About 30 years ago, Michael Linenberger, MD, then a junior faculty hematologist, and his colleagues at...

February 2021 Issue

On location

Fostamatinib Improves Hemoglobin Levels in Warm Autoimmune Hemolytic Anemia

Monday, February 1st, 2021
Treatment with the oral Syk inhibitor fostamatinib led to “markedly improved” hemoglobin (Hb) levels in patients with warm autoimmune hemolytic anemia (wAIHA), according to...
On location

Teclistamab Shows Promise for Myeloma in Phase I Trial

Monday, February 1st, 2021
Approximately three-quarters of patients with relapsed and/or refractory multiple myeloma (MM) responded to treatment with the bispecific antibody teclistamab, according to results from a...
On location

CRISPR Gene Editing May Offer Curative Potential for Sickle Cell Disease

Monday, February 1st, 2021
CRISPR-based gene editing techniques may offer curative potential for sickle cell disease (SCD) when used to target Krüppel-like factor 1 (KLF1) mutations, according to...
On location

Long-Term BELIEVE Analysis Finds Luspatercept Alleviates Transfusion Burden in Patients With Beta Thalassemia

Monday, February 1st, 2021
A longitudinal analysis of data from the phase III BELIEVE trial showed that treatment with the activin receptor ligand trap luspatercept was associated with...
On location

Venetoclax and Azacitidine Combination Associated With Durable Responses in Higher-Risk MDS

Monday, February 1st, 2021
More than three-quarters of patients with higher-risk, treatment-naïve myelodysplastic syndromes (MDS) responded to the combination of venetoclax plus azacitidine, according to study results presented...
On location

Testing for Inherited Thrombophilias Provides Limited Benefit

Monday, February 1st, 2021
Inherited thrombophilias are associated with an increased risk of initial and recurrent venous thromboembolism (VTE), but testing for these conditions in the setting of...